Long-term administration of escitalopram in patients with social anxiety disorder in Japan
Satoshi Asakura,1 Taiji Hayano,2 Atsushi Hagino,2 Tsukasa Koyama3 1Health Care Center and Department of Psychiatry, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, 2Clinical Development Planning and Management, Mochida Pharmaceutical Co., Ltd, Tokyo, 3Clinical Research Center, O...
Enregistré dans:
Auteurs principaux: | Asakura S, Hayano T, Hagino A, Koyama T |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2016
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/ddd26b8fa0014e00ae56de71289a6a15 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial
par: Jeffrey R. Strawn, et autres
Publié: (2021) -
Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series
par: Yamaguchi Y, et autres
Publié: (2018) -
Efficacy and tolerability of escitalopram in treatment of major depressive disorder with anxiety symptoms: a 24-week, open-label, prospective study in Chinese population
par: Jiang KD, et autres
Publié: (2017) -
Selective serotonin reuptake inhibitors may lead to improved cataract surgery outcomes in patients with amblyopia
par: Xin KZ, et autres
Publié: (2019) -
A meta-analysis of effects of selective serotonin reuptake inhibitors on blood pressure in depression treatment: outcomes from placebo and serotonin and noradrenaline reuptake inhibitor controlled trials
par: Zhong Z, et autres
Publié: (2017)